Determining Optimal Treatment to Correct Preoperative Anemia and Reduce Perioperative Allogeneic Blood Transfusions in Cardiac Surgery: A Retrospective Cohort Study

Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update

“…25 One nonrandomized study was published in 2022, 26 while 5 non-randomized studies were published in 2021. [27][28][29][30][31] Five of the non-randomized studies were retrospective cohort studies that used historical patient data in their analysis. [26][27][28][29][30] One non-randomized study was a multicenter prospective cohort study that used prospectively collected patient data.…”

“…[27][28][29][30][31] Five of the non-randomized studies were retrospective cohort studies that used historical patient data in their analysis. [26][27][28][29][30] One non-randomized study was a multicenter prospective cohort study that used prospectively collected patient data. 31 When reported, patient follow-up time varied across studies depending on the outcome being reported, but ranged from 21 days to 3 months.…”

“…Six SRs [16][17][18][19][20][21] including 3 with meta-analysis (MA), 16,17,19 4 RCTs, [22][23][24][25] 6 non-randomized studies, [26][27][28][29][30][31] and 1 evidence-based guideline 32 was included in this report.…”

Coagulation and Transfusion Updates From 2021

“…This approach was assessed in a retrospective Canadian cohort study, including 532 patients referred to an outpatient blood conservation clinic before cardiac surgery. 57 The authors found that the preoperative treatment with iron and erythropoietin significantly increased hemoglobin values. Based on their analyses, intravenous iron at a dose of at least 600 mg, and erythropoietin alfa at doses of at least 80,000 units, were necessary to increase hemoglobin values.…”

“…Based on their analyses, intravenous iron at a dose of at least 600 mg, and erythropoietin alfa at doses of at least 80,000 units, were necessary to increase hemoglobin values. 57 This study highlighted 2 major problems in current preoperative PBM programs: First, the number of eligible patients was limited, given that roughly 530 included patients were recruited over a time period of about 10 years. Second, the high doses of iron and erythropoiesis-stimulating agents required for hemoglobin optimization might question the cost-effectiveness.…”